{"id":"NCT00828191","sponsor":"IBSA Institut Biochimique SA","briefTitle":"Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)","officialTitle":"Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-07","completion":"2012-02","firstPosted":"2009-01-23","resultsPosted":"2012-12-26","lastUpdate":"2013-01-31"},"enrollment":800,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["In Vitro Fertilization"],"interventions":[{"type":"DRUG","name":"Progesterone","otherNames":[]},{"type":"DRUG","name":"Progesterone","otherNames":[]}],"arms":[{"label":"Progesterone SC","type":"EXPERIMENTAL"},{"label":"Progesterone Tablets","type":"ACTIVE_COMPARATOR"}],"summary":"Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy and tolerability of a new progesterone formulation to be used for luteal support in IVF (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.","primaryOutcome":{"measure":"Ongoing Pregnancy Rate","timeFrame":"10 weeks after treatment start","effectByArm":[{"arm":"Progesterone SC","deltaMin":40.8,"sd":null},{"arm":"Progesterone Tablets","deltaMin":43.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.52"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["30895243","25100106"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":400},"commonTop":["Headache","Breast pain/tenderness","vaginal hemorrage","Injection site discomfort","Vaginal discharge"]}}